News

Article

Study: Risk of Atrial Fibrillation Remains High After 3 Years, Including Those With Heart Failure

Risk of atrial fibrillation with 1 of the independent predictors, including congestive heart failure and left atrial enlargement, resulted in greater than a 4-fold increased detection.

The risk of atrial fibrillation (AF) detection after stroke due to large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD) was shown to last beyond 1 year for patients with insertable cardiac monitors (ICMs), with heart failure (HF) and left atrial enlargement (LAE) being significant risk factors, according to results from the STROKE AF study (NCT02700945).

Elderly woman feeling heart pain, touching chest with both hands. | Image Credit: fizkes - stock.adobe.com

fizkes - stock.adobe.com

Results of the study, published in JAMA Neurology, showed that the detection with ICMs increased from 12.5% at 1 year to 21.7% at 3 years, compared to the 2.4% detection rates from the standard monitoring. Most AF cases in the ICM group were asymptomatic, with most patients having at least 1 episode that was longer than 1 hour, according to the results.

The STROKE AF study was conducted at 33 sites in the United States, enrolling 496 individuals from April 2016 to July 2019, with a follow up through July 2022, according to the study authors. For this part of the study, individuals with ischemic stroke were classified by Trial of Org 10172 in acute stroke treatment (TOAST) criteria to determine if the cause was by LAD or SVD. They were randomized to either receive an ICM or site-specific standard-of-care within 10 days of stroke.

Individuals included were also aged 60 years or older, or aged 50 to 59 with at least 1 stroke risk factor, including heart failure, hypertension, diabetes, ischemic stroke more than 90 days before index stroke, or other ischemic vascular disease, according to the study authors. The median age of individuals included in the study was 66 years, with 37.6% being women and a median CHA2DS2-VASc Score for Atrial Fibrillation Stroke Risk of 5.

Investigators noted that there was a median follow up of 29.4 months with 21 crossovers during the follow-up, including: 8 assigned to ICM after never receiving it, 5 assigned to ICM switched to the usual care more than 1 year after ICM insertion, and 8 assigned to the usual care that received an ICM in the follow-up.

The study authors noted that the AF detection levels increased in the ICM group throughout the study, with 2.6% at 1 month, 7.9% at 6 months, 12.5% at 1 year, and 18.5% at 2 years. The median time to AF detection was 9.3 months with ICM and 6.8 months for the control group. Investigators also found 20.5% of individuals in the ICM group had at least 1 day where 1 hour or more of AF burden was detected by year 3, according to the results.

Furthermore, the investigators found that at least 1 of the independent predictors, including body mass index, congestive HF, LAE, and QRS duration, resulted in greater than a 4-fold increase in AF detection by 3 years compared to individual who did not have any AF predictors. The study authors noted, “patients with [LAE], [HF], obesity, or prolonged QRS may constitute high-risk groups in which monitoring might be most cost-effective.”

They also said that AF is common for patients after stroke with noncardioembolic causes, and monitoring by physicians should take place after 1 year, as the patient’s risk increased for at least 3 years after stoke, according to the result of the study.

Reference

Bernstein RA, Kamel H, Granger CB, et al. Atrial Fibrillation In Patients With Stroke Attributed to Large- or Small-Vessel Disease: 3-Year Results From the STROKE AF Randomized Clinical Trial. JAMA Neurol. doi:10.1001/jamaneurol.2023.3931

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards